Navigation Links
Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
Date:12/4/2007

REDWOOD CITY, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, announced today the license of its proprietary dengue virus antigen technology to sanofi pasteur, the vaccines division of the sanofi-aventis Group.

Under the terms of the agreement, Maxygen will transfer to sanofi pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second generation vaccine. In addition to royalties, total event payments to Maxygen, including an upfront fee, could total $24.5 million.

The dengue virus is a mosquito-borne pathogen that infects over 50 million people each year, causing 500,000 hospitalizations for Dengue Hemorrhagic Fever/ Dengue Shock Syndrome, according to The World Health Organization (WHO). Without proper treatment, Dengue Shock Syndrome can be fatal.(1) WHO estimates that more than 20,000 people worldwide, mainly children, die each year from infection with the virus. While the majority of deaths occur in tropical and subtropical regions, the virus is spreading to new regions of the world, including Northern Australia, the Middle East, Central America, and the southern part of the United States. WHO estimates that 40 percent of the world's population is currently at risk of dengue infection.(2)

To date, efforts to develop a dengue vaccine have been challenged by the existence of four different serotypes of dengue virus, all of which are responsible for the severe form of the disease called Dengue Hemorrhagic Fever. To overcome this challenge, Maxygen used its proprietary MolecularBreeding(TM) directed molecular evolution platform. Segments of DNA fro
'/>"/>

SOURCE Maxygen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Maxygen Announces Hold on MAXY-alpha Development Program
2. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
3. Maxygen Announces Upcoming Webcasts at Investor Conferences
4. Maxygen Reports Third Quarter 2007 Financial Results
5. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
8. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
9. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
10. Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
11. HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...menopause to postmenopause , , MONTVALE, N....y and intensity of vasomotor symptoms is a challen...nt and The Journal of Family Practice have rece...toms: Managing the transition from perimenopause t...or, MD, CM and Lee P. Shulman, MD, discuss the ben...
(Date:12/2/2008)...Applied BioSciences has turned to MBI Internationa...cial viability of an important bio-based product l... gap between research and commercialization throug...es. MBI’s unique “Collaborative De-Ris...ological uncertainties, which impede new technolog...
(Date:12/2/2008)...wire/ -- GeneGo, Inc., the leading systems biology...ecome a certified GeneGo Center of Excellence. Bur... to GeneGo,s MetaCore data analysis suite, trainin...a world-class biomedical research facility running...ny departments, including research in cancer, stem...
(Date:12/2/2008)...wire/ -- Intradigm Corporation, a leading,develop...herapeutics, today,announced the issuance of Unit... Compositions for Controlling Efficacy of RNA Sile... seminal research of Philip Zamore, Ph.D., the,Gr... Professor of Biochemistry,& Molecular Pharma...
Breaking Biology Technology: DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product 2The Burnham Institute for Medical Research Becomes a GeneGo Center of Excellence Using MetaCore for Stem Cell Research and Neurology 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 2Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics 3
... Wis. - This summer, venture investors deployed m...s Wisconsin, a total that may bode well for improv...ile it is difficult to draw firm conclusions from ...ld indicate that technologically innovative compan...ase of capital in 2006. , ,"With the growth of the...
... Wis. - The Madison-based National Stem Cell Ban...tem cells from the University of California-San F...available on the federal registry. , ,Beth Donley,...ute , which houses the stem cell bank, said the or...ave all 21 federally approved lines. , ,"We,re ver...
...Wis. - The Center for Advanced Technology and In...ogy-based economic development programs. , ,An awa...uncil recognizes CATI,s work in developing a $40 ...uch as Kraft Foods , S.C. Johnson , and Boeing ...ments, five company product line expansions, and t...
... Wis. - Genetically engineered mice are very expe...ny has developed a method for producing similarly ...io Corp. , a privately-held biopharmaceutical firm...urdles associated with producing modified mice at ... animals instead. , ,Mirus has begun using its spe...
Other Biology Technology:Summer venture investments total $18 million for Wisconsin start ups 2Summer venture investments total $18 million for Wisconsin start ups 3Summer venture investments total $18 million for Wisconsin start ups 4Nation's only stem cell bank will receive UC-San Francisco cell line 2Mirus provides low-cost way to modify genes 2
(Date:12/2/2008)...ywhere else in the world. This is having a major i...nvironment and effect of cities on rural areas. On...ca,s history is being over-looked. , Joy Clancy ...blem in the current issue of the African Journal ...the African population was rural, today 38% live i...
(Date:12/2/2008)...tion due to climate change, pollution and human ac... providing satellite data of the region for the la...ion with ESA,s future missions will be key in impl...icy called ,The European Union and the Arctic Regi...n the region such as the opening up of long-sought...
(Date:12/1/2008)...spread consumption advisories and uncertainty amon...w researchers at North Carolina State University h...d regulators around the country predict which area... a breakthrough that should help officials addres...es for specific water bodies and fish species. , ...
(Date:12/1/2008)...old a colloquium to examine what lies ahead in evo...isms. Leading researchers and students will discus...tion and even evolution from the perspectives of e...ity informatics dealing with microbes, plants, and...he event will take place at the Arnold and Mabel B...
Breaking Biology News(10 mins):ESA satellites focusing on the Arctic 2New model predicts hot spots for mercury in fish 2American Council on Exercise Offers 10 Tips for Surviving the Holidays 2847 1American Council on Exercise Offers 10 Tips for Surviving the Holidays 2847 2IDM Pharma to Present at BIO InvestorForum in San Francisco 1045 1IDM Pharma to Present at BIO InvestorForum in San Francisco 1045 2IDM Pharma to Present at BIO InvestorForum in San Francisco 1045 3Environmental Tectonics Corporations BioMedical Division Announces New Contract 1042 1Environmental Tectonics Corporations BioMedical Division Announces New Contract 1042 2Environmental Tectonics Corporations BioMedical Division Announces New Contract 1042 3Clarient Names Michael J Pellini M D Chief Operating Officer 2845 1Clarient Names Michael J Pellini M D Chief Operating Officer 2845 2Clarient Names Michael J Pellini M D Chief Operating Officer 2845 3Clarient Names Michael J Pellini M D Chief Operating Officer 2845 4
...wly identified gene expression profile could help ...will respond to chemotherapy treatment. Described ...urnal of Clinical Oncology (JCO), the new findings...y gene profiling as a predictor of clinical outcom...clinicians with insights into the mechanisms of dr...
... preliminary results from a study in Botswana, Har...d that people with HIV-1 subtype C in resource-poo...py, can achieve comparable results to those in the...livery system and infrastructure help ensure this ...005 issue of the Journal of Acquired Immune Defici...
...am of researchers led by scientists at Memorial Sl... new class of drugs -- now in early stage clinical... the BRAF gene. BRAF is a protein that plays a cen...ls and is mutated in the majority of patients with..., breast, and lung cancers. The findings, availabl...
...rding to research reported this week in Current Bi...e epicenter of the 2004 Sumatra-Andaman earthquake...mited, particularly when compared to damage from c...0 days after the tsunami of December 26, 2004, a t...Wildlife Conservation Society-Indonesia Program, a...
Other Biology News:Gene expression profile helps predict chemotherapy response in ovarian cancer patients 2Gene expression profile helps predict chemotherapy response in ovarian cancer patients 3New Therapeutic Target Identified In Inherited Brain Tumor Disorder 2Mutations in the BRAF gene predict sensitivity to a novel class of cancer drugs 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis.
Request Info
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, glycerol solution.
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates.
Biology Products: